No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HLVX HilleVax
- 1.750
- +0.080+4.79%
Close Jul 12 16:00 ET
- 1.750
- 0.0000.00%
Post 19:42 ET
87.01MMarket Cap-530P/E (TTM)
1.780High1.640Low1.85MVolume1.640Open1.670Pre Close3.22MTurnover7.96%Turnover RatioLossP/E (Static)49.72MShares20.22052wk High0.36P/B40.75MFloat Cap1.55052wk Low--Dividend TTM23.28MShs Float24.420Historical High--Div YieldTTM8.38%Amplitude1.550Historical Low1.734Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a Turnaround
(HLVX) - Analyzing HilleVax's Short Interest
HilleVax's (NYSE:HLVX) short percent of float has risen 14.66% since its last report. The company recently reported that it has 1.55 million shares sold short, which is 20.02% of all regular shares
HilleVax Cut to Market Perform From Outperform by Leerink Partners
HilleVax Cut to Market Perform From Outperform by Leerink
HilleVax Price Target Cut to $3.00/Share From $34.00 by Stifel
HilleVax Price Target Cut to $3.00/Share From $34.00 by
Leerink Partners Downgrades HilleVax(HLVX.US) to Hold Rating, Cuts Target Price to $2
Leerink Partners analyst David Risinger downgrades $HilleVax(HLVX.US)$ to a hold rating, and adjusts the target price from $28 to $2.According to TipRanks data, the analyst has a success rate of 57.6%
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Comments
HilleVax, Inc. Announced Disappointing Results from NEST-IN1 Clinical Study.
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
$HilleVax(HLVX.US$
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
how the F they gonna cut the target from 28 down to 2 just because of failed trial? This company has pretty sound finances and their debt to assets is extremely good for this particular field
2
$HilleVax(HLVX.US$ some recovery should come soon :)
1
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg